Novartis Ag (NVS) Current Assets (2009 - 2025)
Novartis Ag recorded quarterly Current Assets of $30.5 billion in Q4 2025, up 17.43% quarter-over-quarter from $25.9 billion in Q2 2025, and up 2.55% year-over-year from $29.7 billion in Q4 2024.
Novartis Ag's Current Assets history runs 12 years deep, the most recent figure standing at $30.5 billion for Q4 2025.
- In Q4 2025, Current Assets rose 2.55% year-over-year to $30.5 billion; the TTM figure through Dec 2025 stood at $30.5 billion (up 2.55% YoY), while the FY2025 annual figure was $30.5 billion, up 2.55% from the prior year.
- Current Assets came in at $30.5 billion for Q4 2025 at Novartis Ag, up from $25.9 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $45.7 billion in Q4 2021 to a low of $25.7 billion in Q2 2024.
- A 5-year average of $32.8 billion and a median of $30.9 billion in 2021 frame the typical range for Current Assets.
- Across the five-year window, Current Assets soared 54.07% in 2021 and fell 23.29% in 2024, its largest moves.
- Novartis Ag's Current Assets stood at $45.7 billion in 2021, then fell by 19.27% to $36.9 billion in 2022, then fell by 17.42% to $30.5 billion in 2023, then retreated by 2.55% to $29.7 billion in 2024, then advanced by 2.55% to $30.5 billion in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $30.5 billion, $25.9 billion, and $29.7 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 54.84 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 59.17 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 33.53 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 27.21 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 23.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 30.46 Bn |
| Jun 30, 2025 | 25.94 Bn |
| Dec 31, 2024 | 29.70 Bn |
| Jun 30, 2024 | 25.69 Bn |
| Dec 31, 2023 | 30.48 Bn |
| Jun 30, 2023 | 33.49 Bn |
| Dec 31, 2022 | 36.91 Bn |
| Jun 30, 2022 | 38.14 Bn |
| Dec 31, 2021 | 45.72 Bn |
| Jun 30, 2021 | 31.30 Bn |
| Dec 31, 2020 | 29.67 Bn |
| Jun 30, 2020 | 27.70 Bn |
| Dec 31, 2019 | 29.50 Bn |
| Jun 30, 2019 | 32.30 Bn |
| Dec 31, 2018 | 35.56 Bn |
| Jun 30, 2018 | 29.60 Bn |
| Dec 31, 2017 | 28.21 Bn |
| Dec 31, 2016 | 24.93 Bn |
| Mar 31, 2010 | 35,800.00 |
| Dec 31, 2009 | 33,691.00 |
| Sep 30, 2009 | 30,440.00 |
| Jun 30, 2009 | 27,172.00 |
| Mar 31, 2009 | 22,482.00 |